Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

Abe, Koji; Itoyama, Yasuto; Sobue, Gen; Tsuji, Shoji; Aoki, Masashi; Doyu, Manabu; Hamada, Chikuma; Kondo, Kazuoki; Yoneoka, Takatomo; Akimoto, Makoto; Yoshino, Hiide; behalf of The Edaravone ALS Study Group, on

doi:10.3109/21678421.2014.959024

Public

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

Published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration • Oct 6, 2014

Authors:

Koji Abe

Yasuto Itoyama

Gen Sobue

Abstract

Our objective was to confirm the efficacy and safety of edaravone in amyotrophic lateral sclerosis (ALS) patients. We conducted a 36-week confirmatory study, consisting of 12-week pre-observation period followed by 24-week treatment period. Patients received placebo or edaravone i.v. infusion over 6...

Subject

Edaravone

Amyotrophic lateral sclerosis

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!